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It might come as a surprise tomany, that stem cell transplantation is
actually an established, life saving therapy for certain diseases affecting
the haematological system and stratiﬁed epithelia. This ismade possible
by the chemical (chemotherapy) or physical (radiation) ablation of the
affected bone marrow or surgical removal of diseased epithelia. The
elimination of affected tissues thus makes “room” for donor cells,
which consequently engraft with high yields, effectively replacing
the diseased tissue with a healthy one.
This is, at the state of the art, clearly an impossible task formost tissues
such as the brain and cardiac or skeletal muscles. Furthermore, intrinsic
structural and functional differences among different tissues affect trans-
plantation outcome. Finally and just as important, long-term stem cell
self-renewal differs dramatically among different tissues, signiﬁcantly
impacting on the long-term regeneration potential of each tissue. It is
mostly for these reasons that attempts to treat degenerative diseases of
other tissues such as brain or heart with cell therapy, have so far met
with generally modest results at best.
In the last twenty years, gene therapy has moved, not without
considerable problems, into the clinical arena, and cell-mediated gene
therapy especially has produced encouraging, and in some case striking
results, again for genetic diseases of blood and epithelia.
Hundreds of clinical trials have started, are running or have been
completed for diseases of different tissues. While many remain unpub-
lished, the results of some are becoming available, together with
valuable experience gained fromboth successful and unsuccessful trials.
This information will be of critical importance to reﬁne protocols andG. Cossu), roberto.buccione@
e Luca).
. This is an open access article underimplement tools aimed at achieving clinical efﬁcacy. Unfortunately,
however, many poorly controlled trials are also taking place and will
inevitably bring confusion to a growing ﬁeld; poorly controlled trials
will also raise unjustiﬁed expectations in desperate patients and/or
their parents who cannot evaluate the soundness of trials that they
learn about through the social media.
For all of these reasons, we felt that a conference speciﬁcally focused
on the clinical translation of stem cell-based research, on running trials
and their follow-up and their impact on society, was sorely needed to
offer a timely picture of such a rapidly evolving and partly controversial
ﬁeld.
2. The topics
Given the broad and sometimes ill-deﬁned distinctions among the
various disciplines, we decided to focus on both allogeneic and autolo-
gous genetically corrected cell therapy, with the exclusion of “in vivo”
gene therapy (Fig. 1), and cancer or basic stem cell biology, all huge
areas in their own right and covered in many other excellent meetings.
The conference was funded by the EMBO Courses and Workshops
Programme and co-sponsored by the University of Manchester, with
contributions from e-Life, Holostem Terapie Avanzate and the patient
associations, “Duchenne Parent Project — Italy” and ReACT.
3. What is working or promises to?
Each session was dedicated to diseases predominantly affecting a
tissue/organ, namely the haematopoietic system, epithelia, skeletal
and cardiac muscle, brain and bone, with a keynote lecture by Kathryn
Wood (Oxford University), dedicated to the immunological hurdles in
cell transplantation and describing the underlyingmechanisms together
with strategies that might be implemented to overcome undesirablethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Anover-simpliﬁed scheme of gene therapy, cell therapy and tissue engineering, also
showing the basic science and technology that feeds into these disciplines. The
scheme also shows the stage of the pathological process where new therapies should
promote regeneration and prevent ﬁbrosis and tissue failure.
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to the ethical and regulatory issues arising from this new and rapidly
evolving area of medicine.
Below, we will mention a few examples of the exciting new results
presented at the meeting, keeping in mind that the long-term follow-
up of a cell-based therapy is equally important, albeit less exciting and
“glamorous” than a report on a new successful outcome of cell therapy
for a disease. We apologize to those speakers who we could not quote
due to space constraints (the complete list of speakers is available at:
http://events.embo.org/15-cell-therapy).
The Conference was opened by a keynote lecture by Luigi Naldini
(TIGET, San Raffaele), who gave an overview of the current state of
ex-vivo gene/cell therapy and provided an update on the on-going
metachromatic leukodystrophy trial (Bifﬁ et al., 2013), the follow up
of the ﬁrst successfully treated patients, as well as on the new gene
transfer tools that may soon enter the clinical arena.
In the haematological diseases session, several leaders in the ﬁeld
reported on the state of the art of the on-going or pending trials for
the treatment of Wiskott–Aldrich syndrome (Alessandro Aiuti, TIGET,
Milan), SCID, haemoglobinopathies (Marina Cavazzano, Necker, Paris)
and Fanconi anaemia (Jaun Bueren, CIEMAT, Madrid). Clearly, each
one of these diseases poses different biological and clinical problems
(reviewed in Cicalese and Aiuti, 2015; Cavazzana et al., 2016). The
approach undertaken, though tailored for each speciﬁc disease, is,
nevertheless always based on auto-transplantation of gene corrected
autologous haematopoietic stem cells (HSCs). The results appear quite
promising and the coming years will inform us on efﬁcacy, as in the
case of ADA deﬁciency, now celebrating the ﬁfteenth year of follow up
of the ﬁrst treated patient.
New trials have started or will start shortly in the epithelial cell
arena for different forms of epidermolisis bullosa, after quite a long
interval from the ﬁrst reported positive results (De Rosa et al.,
2013). Initial promising results were reported at the conference
(Michele De Luca, University of Modena and Peter Marinkovich,
Stanford University). May Grifﬁth (Linköping University) reported
on new biomaterials for cornea bioengineering and Graziella
Pellegrini (University of Modena) reported extensively on follow
up and new developments for corneal regeneration by means of
cultured limbal stem cells, both for total unilateral and partial bilateral
ocular burns (Pellegrini and De Luca, 2014), which recently received
conditional market authorisation. The exciting possibility of using a
different source of stratiﬁed epithelium, such as the oral mucosa, for
complete bilateral corneal destruction was also presented as a very
preliminary observation.4.…and where there is a longer road ahead
Progress is beingmade at a rapid pace for certain neurodegenerative
conditions such as Parkinson's disease and multiple sclerosis (MS),
although based on different approaches. In the ﬁrst case, the localized
nature of neuronal damage suggested more than a decade ago that
cell replacement therapywas a pursuable option. Roger Barker (Univer-
sity of Cambridge) presented an outstanding overview of research over
the last twenty years, starting with the pioneering transplantation of
foetal midbrain, to more recent approaches using neural stem cells
and ending with some of the challenges that the ﬁeld currently faces
and how they may be resolved (Barker et al., 2015).
In contrast, MS, like most degenerative diseases of the central
nervous system, affects extensive regions, making a complete cell
replacement approach amajor challenge. However, MS also well exem-
pliﬁes how crucial it is to understand the molecular pathogenesis of a
speciﬁc disease in order to devise meaningful and possibly efﬁcacious
therapies as discussed by Robin Franklin (University of Cambridge)
and Gianvito Martino (San Raffaele, Milan). As mentioned above, local-
ized versus widespread distribution of tissue damage remains a crucial
issue in determining feasibility, outcome and how rapidly beneﬁt may
be reached. In this respect, another example reported at the conference
was cell therapy for a localized form of muscular dystrophy (oculo-
pharyngeal), which results in a modest but partially efﬁcacious
engraftment (Gill Butler-Browne, Myologie, Paris) (Périé et al., 2014),
whereas systemic delivery of donor cells to patients affected by
Duchennemuscular dystrophy, while safe andwell-tolerated, produced
a level of engraftment that was too low to produce signiﬁcant efﬁcacy
(Giulio Cossu, University ofManchester), presumably due to the severity
of the disease and the advanced age of the patients, selected for safety
reasons (Cossu et al., 2015). Moving from skeletal to cardiac muscle,
the landscape does not change: in this case, many clinical trials have
been carried out in the past (Assmus et al., 2015) and were brieﬂy
described at the Conference. Simple cell transplantation is unlikely to
be efﬁcacious for either acute or chronic heart diseases. Indeed, different
strategies were presented by Kenneth Chien (Karolinska, Stockholm)
and Stefanie Dimmeler (University of Frankfurt) ranging from delivery
of modiﬁed mRNA or miRNA to promote endogenous regeneration
(Sahara et al., 2015) to in vitro models of various cardiac diseases
created with induced pluripotent stem cell-derived cardiomyocytes
(Joseph Wu, Stanford University) (Ebert et al., 2015). Likewise, in
the case of muscular dystrophy, strategies to correct neighbouring
resident nuclei (taking advantage of the multinucleated nature of
the tissue) and combination with other gene/drug therapies appear
as a possible way forward to overcome the major hurdle of poor
engraftment.
The scientiﬁc session on bone raised many issues and touched upon
controversial topics. The bone marrow contains, in addition to the
haematopoietic stem cells (HSCs), another population of adherent,
clonogenic cells that have the ability to generate bone, cartilage and
marrow fat; i.e., the cell types of the organ where they are resident.
Such cells, usually referred to collectively as “mesenchymal stem cells”
should rather be termed “skeletal stem cells” since they are speciﬁcally
derived from bone (Bianco and Robey, 2015). In fact, cells with similar
characteristics but different potency have been identiﬁed in many
tissues of mesodermal origin. Despite their different speciﬁcities, such
cells, are being utilized indiscriminately in hundreds of clinical trials
worldwide, irrespective of their origin, and for a plethora of different
diseases based on alleged immune modulatory and anti-inﬂammatory
paracrine effects, often if not always in the absence of any real pre-
clinical evidence, bio-distribution studies and rigorous endpoints to
evaluate their efﬁcacy (Bianco, 2014). The speakers of this session
(Pamela Gehron Robey, NIH and Paolo Bianco, University of Rome)
reiterated the clear difference between trials using these cells for
repairing congenital or acquired diseases of cartilage and bone and the
remaining, far less deﬁned, questionable trials. The latter unfortunately
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treatments offered by private stemcell clinics of questionable reputation
to patients with incurable diseases, unable to make informed and
non-emotional decisions. Even with rigorous trials, an accurate char-
acterization of bona ﬁde “mesenchymal stem cells” revealed that the
preparations are signiﬁcantly heterogeneous depending on the
centre producing them. Nevertheless, positive results in repairing
long bone defects (in conjunction with appropriate biomaterials)
were reported by Frank Luyten, (Leuven University). A careful analysis
of the pathogenesis of ﬁbrous dysplasia also led to an important conclu-
sion: if the underlying molecular mechanism is fully understood and
drugable, cell replacement is not an obligatory route (Paolo Bianco,
University of Rome).
5. The ethics of cell therapy
Clearly then, cell therapy and regenerative medicine in general raise
a number of ethical, economical and regulatory issues that were
addressed in an ad hoc session. As a general introduction to this very
complex landscape, John Harris (University of Manchester) took lead
from vintage and recent cases such as in vitro fertilization and germ
cell genome editing (Chan et al., 2015), to discuss how science and
technology should harness public support while deﬂecting the
emotional reactions that may affect the development of the ﬁeld and
its impact on patients' expectancies and their quality of life.
This consideration leads to the subsequent question; i.e., how do we
make appropriate judgments on what is best for the “public good” and
eventually help inform the decisions of policy makers in such a rapidly
evolving ﬁeld? David Napier (University College London) offered an
example by discussing how and why scientists, bioethicists and econo-
mists should prioritize highly individualized and very expensive thera-
pies, whose development impacts directly or indirectly on the general
population. Setting aside the unregulated stem cell “therapies,” the
conundrum presented by the social and ethical justiﬁcation for these
new therapies remains evident. It was pointed out, however, that if
found to be really efﬁcacious, these therapies would actually lead to a
signiﬁcant economic beneﬁt by eliminating the long lasting and
expensive palliative therapies, and returning patients to a normal
and productive life. Finally, from a legal standpoint, the advancement
of regenerative medicine, while protected by “The right and liberty of
scientiﬁc research,” as explicitly recognized by the Constitutions of
several European countries and by the European Union, impinges on
the liberty and dignity of those involved in scientiﬁc research and ex-
perimental trials. Amedeo Santosuosso (University of Pavia) underlined
how scientiﬁc research should not supersede the liberty and dignity of
patients (and relatives) involved, and experimentation must be carried
out according to rules accepted within the scientiﬁc community. These
rules should guarantee that patients are not exposed to avoidable
and harmful risks, especially without a fully open and understand-
able informed consent. Therefore, legislators cannot impose (within
the constraints outlined above) technical and medical standards to
researchers and physicians, nor should the judiciary impose admin-
istration of a non-validated, unapproved experimental therapy. The
legal aspects are obviously very complex and challenging not only for
the scientists, who have to offer safe criteria to the community, but also
for jurists and courts, who must accept that rights (even fundamental
ones) do not necessarily come ﬁrst (Santosuosso et al., 2007). Clearly, asingle session in a meeting could not possibly address all the important
legal and ethical issues that cell therapy faces and will face in the future,
but it is of fundamental importance to bring together the different com-
munities and encourage them to openly discuss these overarching issues.
6. Conclusions
Themeeting could not cover all the different areas, given the limited
time available and the need to discuss in depth the complexity and the
speciﬁcity of each individual therapy for a number of tissues/diseases.
However, some generally applicable messages emerged. The ﬁrst and
most obvious conclusion is that a “one serves all” cell therapy does not
and will not exist at least in a foreseeable future. On the very positive
side, a number of remarkable achievements were reported, as well as
possible solutions to address cases where success is still to be achieved.
The conference also highlighted the important socio-economical and
ethical implications of cell therapy, which also poses complex but not
unsolvable problems.
We all hope, in fact, that in a not too distant future, consolidated,
economically feasible, life-saving cell-based therapies will be available
to treat an ever-increasing number of genetic and acquired diseases.
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